Key result
Eriodictyol significantly attenuated myocardial ischemia-reperfusion injury by improving hemodynamic parameters, reducing infarct size, and decreasing apoptosis and inflammation through JAK2 activation.
Why the study?
Does eriodictyol attenuate myocardial ischemia-reperfusion injury in an ex vivo rat model?
Does eriodictyol attenuate myocardial ischemia-reperfusion injury in an ex vivo rat model?
p-value: p=<0.05
Eriodictyol protects against myocardial ischemia-reperfusion injury in an ex vivo rat model by reducing inflammation and apoptosis through the activation of the JAK2/STAT3 signaling pathway.
Hypothesis-generating for eriodictyol in myocardial I/R injury; leaves open whether JAK2-mediated effects translate clinically.
Myocardial ischemia-reperfusion (I/R) injury remains the leading risk factor of disability and mortality worldwide. In this study, the myocardial protective effect of eriodictyol (EDT) and the underlying mechanism in an ex-vivo model of global myocardial I/R was investigated. After treatment with different concentrations of EDT, the decreased hemodynamic parameters induced by myocardial I/R injury were significantly attenuated by EDT. The elevated levels of IL-6, CRP, IL-8 and TNF-α were effectively reduced by EDT treatment. EDT also remarkably suppressed the levels of Bax and cleaved Caspase-3, and up-regulated the level of Bcl-2 in cardiac tissues from EDT-treated groups. Further studies showed that EDT could increase the levels of p-JAK2 and p-STAT3 in cardiac tissues. Meanwhile, treatment of AG490, a specific inhibitor of JAK2, abolished the protective effect of EDT on hemodynamic parameters, myocardial inflammation and myocardial cell apoptosis induced by I/R injury. These results demonstrated that EDT could protect against myocardial I/R injury through the activation of JAK2, providing a potential treatment with EDT during myocardial I/R injury.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied Myocardial ischemia-reperfusion injury (n=90). Eriodictyol vs. Ischemia-reperfusion without Eriodictyol was evaluated on Myocardial infarct size and hemodynamic parameters (p=<0.05). Eriodictyol significantly attenuated myocardial ischemia-reperfusion injury by improving hemodynamic parameters, reducing infarct size, and decreasing apoptosis and inflammation through JAK2 activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: